A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)

被引：0
|
作者：
Ross, Erin [1 ]
Ram, Lydia [1 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242137
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mixed model time-activity fitting to reduce SPECT/CT imaging time points for dosimetry in Lu-177 peptide receptor radionuclide therapy (PRRT)
    Devasia, Theresa
    Dewaraja, Yuni
    Schipper, Matthew
    Wong, Ka Kit
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [32] Lu-177 DOTA-TATE for peptide receptor radionuclide therapy (PRRT): organ-, tumor- and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S338 - S339
  • [33] Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
    Deville, Agathe
    Pinigina, Iuliia
    Al Mansour, Laure
    Abeillon, Juliette
    Tordo, Jeremie
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : E71 - E73
  • [34] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09) : 1337 - 1340
  • [35] 177Lu DOTATATE nanoparticles: A therapeutic option for peptide receptor radionuclide therapy
    Arora, Geetanjali
    Shukla, Jaya
    Ghosh, Sourabh
    Malhotra, Arun
    Bandohpadhyaya, Guru
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [36] Peptide Receptor Radionuclide Therapy using SSTR antagonists: biokinetics and dosimetry of Lu-177 DOTA-LM3
    Schuchardt, C.
    Wiessalla, S.
    Singh, A.
    Zhang, J.
    Kulkarni, H. R.
    Mueller, D.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S90 - S90
  • [37] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [38] Lymphocytic toxicity in patients after peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
    Paganelli, G.
    Sierra, M. Lopera
    Agazzi, A.
    Bodei, L.
    Pacifici, M.
    Arico, D.
    Grana, C. M.
    Baio, S. M.
    De Cicco, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S351 - S351
  • [39] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Staanum, Peter Frohlich
    Frellsen, Anders Floor
    Olesen, Marie Louise
    Iversen, Peter
    Arveschoug, Anne Kirstine
    EJNMMI PHYSICS, 2021, 8 (01)
  • [40] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Peter Frøhlich Staanum
    Anders Floor Frellsen
    Marie Louise Olesen
    Peter Iversen
    Anne Kirstine Arveschoug
    EJNMMI Physics, 8
12345